OSR Holdings, Inc. (OSRH)
NCM – Real Time Price. Currency in USD
0.46
+0.02 (5.57%)
At close: Mar 27, 2026, 4:00 PM EDT
0.44
-0.02 (-4.33%)
After-hours: Mar 27, 2026, 7:56 PM EDT

NCM – Real Time Price. Currency in USD
0.46
+0.02 (5.57%)
At close: Mar 27, 2026, 4:00 PM EDT
0.44
-0.02 (-4.33%)
After-hours: Mar 27, 2026, 7:56 PM EDT
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
| Name | Position |
|---|---|
| Dr. Constance Hofer | Chief Scientific Officer |
| Mr. Chankyu Park | Chief Executive Officer of RMC |
| Mr. Gihyoun Bang | Chief Financial Officer |
| Mr. Jun Chul Whang | Chief Legal Officer & Director |
| Mr. Kuk Hyoun Hwang | Chairman & CEO |
| Mr. Senyon Choe | Founder & CEO of Darnatein |
| Mr. Tim Smith | Corporate Secretary & Global IR |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | 8-K | ea0281786-8k_osr.htm |
| 2026-03-10 | 8-K | ea0280743-8k_osr.htm |
| 2026-01-27 | 8-K | ea0274230-8k_osrhold.htm |
| 2026-01-14 | 8-K | ea0272738-8k_osrhold.htm |
| 2025-11-25 | 8-K | ea0267127-8k_osrhold.htm |
| 2025-11-12 | 10-Q | ea0264521-10q_osrholdings.htm |
| 2025-10-16 | 8-K | ea0261472-8k_osrhold.htm |
| 2025-09-23 | 8-K | ea0258365-8k_osrholdings.htm |
| 2025-09-09 | 8-K | ea0256727-8k_osrholdings.htm |
| 2025-08-29 | DEF 14A | ea0255195-01.htm |